Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton's jelly-derived exosomes and platelet-rich plasma for recurrent implantation failure
IRCT20170923036334N8Phase 2Recruiting
- Sponsor
- ACECR
- Start
- Jul 2026
- Countries
- 1
01
Overview
Phase 2 trial of platelet-rich plasma in Recurrent Implantation Failure (RIF) (3 arms), sponsored by ACECR. Primary endpoint: Clinical pregnancy rate. Started Jul 2026; status: recruiting.
02
Drugs
platelet-rich plasma
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on IRCT20170923036334N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170923036334N8.